Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMBER
2023-508859-39-00Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in autoimmune hepatitis (AIH) comparing VAY736 with Placebo (2 arms). Primary endpoint: Proportion of patients with normalization of ALT at Week 24. Started Feb 2018; status: completed.
02
Drugs
ianalumab
03
Conditions
autoimmune hepatitis (AIH)
Beyond the preview
Go deeper on 2023-508859-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508859-39-00.